Company profile for Apellis Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. We believe that this approach can result in broad inhibition of the principal pathways of the complement system and has the potential to...
We are a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. We believe that this approach can result in broad inhibition of the principal pathways of the complement system and has the potential to effectively control a broad array of complement-dependent autoimmune and inflammatory diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
6400 Westwind Way, Suite A Crestwood, KY 40014
Telephone
Telephone
(502) 241-4114
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/03/3199410/0/en/The-New-England-Journal-of-Medicine-Publishes-Positive-Phase-3-VALIANT-Results-of-EMPAVELI-pegcetacoplan-for-C3G-and-Primary-IC-MPGN.html

GLOBENEWSWIRE
03 Dec 2025
Apellis Pharma Joins Investor Conferences
Apellis Pharma Joins Investor Conferences

25 Nov 2025

// GLOBENEWSWIRE

https://www.globenewswire.com/news-release/2025/11/25/3194196/0/en/Apellis-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences.html

GLOBENEWSWIRE
25 Nov 2025

https://www.globenewswire.com/news-release/2025/11/12/3186065/0/en/Apellis-Announces-5-Year-GALE-Data-Showing-SYFOVRE-pegcetacoplan-injection-Delayed-Progression-of-Geographic-Atrophy-by-1-5-Years.html

GLOBENEWSWIRE
12 Nov 2025

https://www.globenewswire.com/news-release/2025/11/05/3181254/0/en/Apellis-Pharmaceuticals-to-Present-at-the-Stifel-2025-Healthcare-Conference.html

GLOBENEWSWIRE
05 Nov 2025
Apellis Pharma Reveals Q3 2025 Financials
Apellis Pharma Reveals Q3 2025 Financials

30 Oct 2025

// GLOBENEWSWIRE

https://www.globenewswire.com/news-release/2025/10/30/3177251/0/en/Apellis-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results.html

GLOBENEWSWIRE
30 Oct 2025

https://www.globenewswire.com/news-release/2025/10/20/3169219/0/en/New-One-Year-Data-Reinforcing-the-Robust-and-Sustained-Efficacy-of-EMPAVELI-pegcetacoplan-in-C3G-and-Primary-IC-MPGN-to-be-Presented-at-ASN-Kidney-Week.html

GLOBENEWSWIRE
20 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty